On March 9 Beijing Time (March 8 Eastern Time), the world's leading cancer research organization, the America Association for Cancer Research（AACR）has disclosed the abstract of AACR annual meeting 2022.
6 studies by Simcere researcher were presented in the abstract (including two oral presentations during AACR annual meeting from April 8 to 13, 2022), involving preclinical data on small-molecule targeted drugs, bispecific antibodies and multi-functional T cell engagers independently developed by Simcere. These might bring new insights to cancer scientists, clinicians, patients, and other attendees around the world and raise opportunities for further collaborations.
n A bispecific antibody that synergistically enhances both NK and T cell functions
Session OPO.CL06.01 - Immuno-oncology（E-Poster）
5203 - Discovery and development of SLD2435, a novel humanized IgG1 bispecific antibody simultaneously targeting human TIGIT and PVRIG for cancer immunotherapy
Presenter：Dr. Xiaofeng Zhao
n A targeted therapy with potentially much lower hematologic toxicity
Session MS.ET06.02 - Emerging New Anticancer Agents
2157 - SCR-6277, a potent and high selective arginine methyltransferase 5 (PRMT5) inhibitor with high tumor/plasma distribution ratio demonstrated robust anti-tumor activities and decreased hematological toxicities
Presenter：Dr. Feng Zhou
n A novel multi-specific bivalent T cell engager with strong anti-tumor efficacy
Session PO.IM02.10 - Therapeutic Antibodies 2
2897 / 12 - A multispecific T cell engager binding to both membrane proximal and membrane distal epitopes of MSLN with low affinity CD3 for the treatment of AML and solid tumors
Presenter：Dr. Renhong Tang
n A Highly selective MAT2A inhibitor that addresses off-targeted side effects
Session OPO.ET06.01 - Small Molecule Therapeutic Agents（E-Poster）
5434 - Discovery of SCR-7952, a novel, potent and high selective MAT2A inhibitor shows robust anti-tumor activities and better safety profile
Presenter：Dr. Feng Zhou
n A RAD51 inhibitor that significantly enhances anticancer effect of chemo/targeted therapy
Session OPO.ET06.01 - Small Molecule Therapeutic Agents（E-Poster）
5441 - Discovery of a novel RAD51 inhibitor SCR-6992 targeting homologous recombination pathways in cancer
Presenter：Dr. Wenqing Yang
n A novel CDK2/4/6 inhibitor that overcomes drug resistance
Session OPO.MCB06.01 - Cell Cycle (E-Poster）
5642 - Discovery of SCR-8079, a novel and selective CDK2/4/6 inhibitor overcomes the resistance to CDK4/6 inhibition and demonstrates broad anti-tumor activities in breast cancers
Presenter：Dr. Feng Zhou
About Simcere
Simcere Pharmaceutical Group (2096.HK) is rapidly transitioning to an innovation and R&D-driven pharmaceutical company, with a mission of “providing today’s patients with medicines of the future.” It has established a national key laboratory of translational medicine and innovative pharmaceuticals. Simcere focuses on oncology, central nervous system disease and autoimmune disease therapeutic areas, with a diversified product portfolio and industry-leading capabilities. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading pharmaceutical companies and biotechnology companies, in an effort to bring more global life science breakthroughs to China. For more information, please visit www.simcere.com.